Rubius Therapeutics, Inc.

Rubius reported fourth-quarter 2019 net loss of $44.5 million, or $0.56 per share, versus $27.2 million, or $0.35 per share, in Q4 2018. Full-year 2019 net loss was $163.5 million, or $2.08 per share, versus $89.2 million, or $2.27 per share in 2018. Fourth-quarter R&D spending was $30.5 million versus $16.5 million a year earlier, and G&A was $14.9 million versus $12.6 million. Full-year R&D was $112.4 million versus $51.8 million, and full-year G&A was $57.2 million versus $39.9 million. Cash, cash equivalents and investments were $283.3 million at December 31, 2019, down from $404.1 million a year earlier; management said this provides a cash runway into 2022, improved from prior guidance of mid-2021. For 2020, the company did not give detailed revenue or EPS guidance, but said it expects to initiate RTX-240 clinical development, deliver GMP product from its own facility, file an IND for RTX-321 by year-end, and continue autoimmune discovery work.

Pablo Cagnoni framed the quarter as a strategic pivot toward the programs he believes have the highest potential: oncology and autoimmunity. He emphasized that the decision to stop RTX-134 and deprioritize rare disease was driven by repeated external manufacturing failures, the expense of chronic high-dose enzyme therapy, and the stronger momentum in the oncology pipeline. His tone was confident on internal manufacturing and cautious on near-term clinical readouts, repeatedly stressing that the company is earlier in oncology timing but better positioned operationally now.

Andy Oh walked through the higher spending profile in 2019, driven by R&D investment in the RED PLATFORM, RTX-134, and preclinical/IND-enabling work for oncology programs like RTX-240. He quantified the year-over-year increases in R&D and G&A, and said year-end cash, cash equivalents and investments were $283.3 million. He attributed the improved runway into 2022 to cost savings from the rare disease pullback, lower future CapEx now that the Rhode Island facility is operational, and reallocation of spending toward R&D rather than facility buildout; he also noted a remaining $25 million loan tranche available by June 2020 subject to covenants.

Analysts focused on three main issues: what could be learned from the single RTX-134 patient, how quickly RTX-240 could dose and generate data, and whether Rubius should have moved RTX-134 manufacturing in-house sooner. Management said the RTX-134 data were not interpretable beyond safety, with no adverse events reported, and that the internal manufacturing build took precedence because external transfer would have caused additional delay and required an IND amendment. On RTX-240, management said sites are being opened, dosing will follow a standard oncology dose-escalation design with continued dosing until progression or adverse event, and biopsies will be taken after early doses to assess pharmacodynamic effects.